Levomenthol

CAS 89-78-1

Levomenthol (CAS 89-78-1) is a Phase 3 pharmaceutical compound with 2 bioactivity targets and 59 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Levomenthol

CAS Number

89-78-1

UNII

BZ1R15MTK7

InChIKey

NOOLISFMXDJSKH-KXUCPTDWSA-N

ChEMBL ID

CHEMBL470670

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

Menthol

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL470670 | Small molecule

SOURCE EMBL-EBI ChEMBL 9 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	30000 nM	31	-
-	EC50	38660 nM	5	-
-	IC50	74600 nM	1	-
-	Potency	50.1 nM	1	-
Transient receptor potential cation channel subfamily A member 1 Ion channel	EC50	4.5	-	Homo sapiens
Transient receptor potential cation channel subfamily M member 8 Ion channel	EC50	5.4	-	Mus musculus
Transient receptor potential cation channel subfamily M member 8 Ion channel	EC50	4.2	-	Rattus norvegicus
Transient receptor potential cation channel subfamily A member 1 Ion channel	IC50	4.2	-	Mus musculus
Transient receptor potential cation channel subfamily M member 8 Ion channel	EC50	4.6	-	Homo sapiens

SOURCE DrugCentral 59 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Product adhesion issue	439	2248.705	10069889
Product quality issue	421	1279.09	10069327
Methaemoglobinaemia	116	450.167	10027496
Drug ineffective for unapproved indication	174	360.566	10051118
Gastrointestinal toxicity	91	268.479	10059024
Pulmonary toxicity	91	240.231	10061924
Joint injury	102	202.108	10060820
Neoplasm malignant	97	160.645	10028997
Hepatotoxicity	104	159.952	10019851
C-reactive protein abnormal	90	136.122	10068559
Joint stiffness	83	123.608	10023230
Therapy non-responder	107	108.89	10051082
Injection site inflammation	35	102.208	10022078
Food intolerance	35	101.939	10061958
Musculoskeletal pain	104	100.628	10028391
Drug hypersensitivity	181	86.708	10013700
Musculoskeletal stiffness	121	68.295	10052904
Treatment failure	125	63.531	10066901
No adverse event	62	56.729	10067482
Therapeutic product effect incomplete	94	54.103	10082200
Drug intolerance	146	52.533	10061822
Urosepsis	38	48.96	10048709
Drug ineffective	375	48.617	10013709
Arthropathy	114	47.433	10003285
Urticaria thermal	11	46.404	10061399
Application site irritation	16	45.099	10003046
Infection	126	43.11	10021789
Conjunctival scar	9	40.976	10010733
Application site rash	16	40.25	10003054
Off label use	299	39.861	10053762
Nail bed tenderness	9	36.324	10049268
Application site discomfort	9	34.66	10063072
Administration site erythema	10	34.45	10074796
Condition aggravated	169	30.757	10010264
Pain in extremity	133	29.416	10033425
Anticipatory anxiety	10	29.167	10002758
Toxic anterior segment syndrome	12	27.541	10066366
Dyspepsia	60	26.911	10013946
Pruritus	141	26.78	10037087
Inflammation	53	26.491	10061218
Application site burn	8	23.246	10065059
Pigmentation disorder	14	23.17	10062080
Cyanosis	24	22.592	10011703
Angioedema	41	21.708	10002424
Application site erythema	13	21.26	10003041
Autonomic neuropathy	9	21.219	10061666
Arthralgia	180	20.932	10003239
Vulvovaginal swelling	6	20.083	10071211
Joint swelling	110	20.019	10023232
Toxicity to various agents	21	19.997	10070863

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 6 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
TRPM8 TRPM8	Activator	4.599999904632568 pEC50	15306801
TRPA1 TRPA1	Partial agonist	4.0 pEC50	18815250\|17855602
TRPA1 Trpa1	Antagonist	4.2 pIC50	16829128
TRPM8 Trpm8	Partial agonist	4.1 pEC50	11882888
TRPM8 Trpm8	Partial agonist	4.0 pEC50	15190109\|14757700
TRPV3 Trpv3	Activation	1.7000000476837158 pEC50	16829128

SOURCE NLM RxNorm 7 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
Menthol	6750	SU	MTHSPL
MENTHOL	6750	SU	MTHSPL
menthol	6750	SU	MTHSPL
LEVOMENTHOL	236388	SU	MTHSPL
Levomenthol	236388	SU	MTHSPL
menthol	6750	IN	RXNORM
levomenthol	236388	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Levomenthol used for in pharmaceutical contexts?

Levomenthol (CAS 89-78-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Levomenthol?

Levomenthol has 59 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Product adhesion issue, Product quality issue, Methaemoglobinaemia, Drug ineffective for unapproved indication, Gastrointestinal toxicity. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Levomenthol also used in cosmetics?

No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Levomenthol.

What clinical phase is Levomenthol in?

Levomenthol is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Levomenthol?

Levomenthol has 9 bioactivity rows in this page query. Rendered target entries include Transient receptor potential cation channel subfamily A member 1, Transient receptor potential cation channel subfamily M member 8.